Steroid-free lymphocyte depletion protocols: The potential for partial tolerance?

Contributions to Nephrology

Volumn 146, Issue , 2005, Pages 43-53

  McCauley, Jerry ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; METHODOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE;

FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MALE; PROGNOSIS; RISK ASSESSMENT; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION TOLERANCE;

EID: 16544395448     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (37)

1. United Network of Organ Sharing Website http://www.optn.org/latestData/ rptStrat.asp Based on OPTN data as of June 29, 2004.
2. Brent L: A History of Transplantation Immunology. London, Academic, 1997, pp 230-305.
3. Brent LB: Tolerance and its clinical significance: World J Surg 2000;24:787-792.
4. Brent LB: Tolerance: Then and now. Eur Surg Res 2002;34:154-159.
5. Starzl TE, Murase N, Demetris AJ, Trucco M, Abu-Elmagd K, Gray EA, et al: Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation 2004;77:926-929.
6. Starzl TE, Zinkernagel RM: Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001;1:233-239.
7. Starzl TE, Murase N: Microchimerism, macrochimerism, and tolerance. Clin Transplant 2000;14:351-354.
8. Cosimi AB, Sachs DH: Mixed chimerism and transplantation tolerance. Transplantation 2004;77:943-946.
9. Knechtle SJ, Vargo D, Fechner J, Zhai Y, Wang J, Hanaway MJ, et al: FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997;63:1-6.
10. Cannon JA, Longmire WP: Studies of successful skin homografts in the chicken: Description of a method of grafting and its applications: A technique of investigation. Ann Surg 1952;135:60.
11. Billingham RE, Brent L, Medawar PB: Actively acquired tolerance to foreign cells. Nature 1953; 172:603.
12. Personal communication.
13. Calne R: WOFIE hypothesis: Some thoughts on an approach toward allograft tolerance. Transplant Proc 1996;28:1152.
14. Jonker M, Slingerland W, Ossevoort M, Kuhn E, Neville D, Friend P, et al: Induction of kidney graft acceptance by creating a window of opportunity for immunologic engagement (WOFIE) in rhesus monkeys. Transplant Proc 1998;30:2441-2443.
15. Dresske B, Zavazava N, Huang DS, Lin X, Kremer B, Fandrich F: WOFIE augments the immunosuppressive potency of FK-506. Window of opportunity for immunological engagement. Transpl Immunol 1998;6:243-249.
16. Dresske B, Huang DS, Lin X, Kremer B, Fandrich F: Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. Transplant Proc 1999;31:1561-1562.
17. Dresske B, Zavazava N, Jenisch S, Exner B, Lenz P, El Mokhtari NE, et al: WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. Transplantation 2003;75:1286-1291.
18. Simpson D: T-cell depleting antibodies: New hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 2003;17:147-154.
19. Chakrabarti S, Hale G, Waldmann H: Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: Where do we go from here? Transplant Proc 2004;36:1225-1227.
20. Novitzky N, Rubinstein R, Hallett JM, du Toit CE, Thomas VL: Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: A therapeutic strategy. Transplantation 2000;69:1358-1363.
21. Flynn JM, Byrd JC: Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000;12:574-578.
22. Knechtle SJ: Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 2004;8:106-112.
23. Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, et al: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998;351:1701-1702.
24. Calne R, Moffatt SD, Friend PJ, Jamieson Ny Bradley JA, Hale G, et al: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68:1613-1616.
25. Watson CJ, Firth J, Bradley J, Smith KG, Jamieson NV, Friend PJ, Hale G, Waldmann H, Bradley A, Calne RY: Campath 1H (Alemtuzumab) in renal transplantation: 5-year comparative follow up. Am J Transplant 2004;4:405.
26. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, et al: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody Alemtuzumab (CAMPATH-1H). Transplantation 2003;76:120-129.
27. Knechtle SJ, Pirsch JD, H Fechne J Jr, Becker BN, Friedl A, Colvin RB, et al: Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003;3:722-730.
28. Rao V, Pirsch JD, Becker BN, Knechtle SJ: Sirolimus monotherapy following Campath-1H induction. Transplant Proc 2003;35:S128-S130.
29. Knechtle SJ, Pirsch JD, Voss BJ, Leverson GL, Becker BN, Fernandez LA, Chin LT, Becker YT, Odorico JS, D'Allessandro AM, Sollinger HW: Campath-1h in patients with delayed graft function: Reduced rejection and improved graft survival. Am J Transplant 2004;4:404.
30. Shapiro R, Tan H, Basu A, Khan A, Gray L, Randhawa PS, Murase N, Zeevi A, Demetris AJ, Woodward J, Jordan ML, Ruppert K, Marcos A, Fung JJ, Starzl TL: Campath-1H preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients. Am J Transplant 2004;4:405.
31. Vathsala A, Ona ET, Tan S, Suresh S, Yio Chan Y, Lou H, Cabanayan Casasola CB, Seldrup J, Calne R: CAMPASI: A pilot randomized controlled trial of the effectiveness of Campath-1H as an induction agent for prevention of graft rejection and preservation of renal function in patients receiving kidney transplants. Am J Transplant 2004;4:406.
32. Mueller TF: Thymoglobulin: An immunologic overview. Curr Opin Organ Transplant 2003;8:305-312.
33. Starzl TE, Murase N, Abu-Elmagd K, Gray LA, Shapiro R, Eghtesad B, et al: Tolerogenic immunosuppression for organ transplantation. Lancet 2003;361:1502-1510.
34. Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, et al: Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg 2003;238:520-525.
35. Knechtle SJ, Burlingham WJ: Metastable tolerance in nonhuman primates and humans. Transplantation 2004;77:936-939.
36. Calne RY: Prope tolerance: The future of organ transplantation - From the laboratory to the clinic. Transplantation 2004;77:930-932.
37. Montagnino G, Banfi G, Campise MR, Passerini P, Aroldi A, Cesana BM, Ponticelli C: Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation. Transplantation 2004;78:242-249.